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Natural killer (NK) cells have therapeutic potential for cancer due to their capacity for 
targeting tumor cells without prior sensitization. Our laboratory has developed an NK cell 
expansion protocol that generates large quantities of NK cells for therapeutic infusion 
that secret 20 times the amount of interferon gamma (IFNγ) than resting NK cells. IFNγ 
can upregulate major histocompatibility complex (MHC)-class I, an inhibitory ligand for 
NK  cells, but can also upregulate intercellular adhesion molecule 1 (ICAM-1) which 
promotes NK:target cell interaction for an efficient lysis. Due to the opposing effects 
reported for IFNγ on tumor sensitivity to NK cells, we evaluated a panel 22 tumor cell 
lines from the pediatric preclinical testing program corresponding to different tumor 
types. We determined the impact of IFNγ on their expression of NK cell activating and 
inhibitory ligands, death receptors, and adhesion molecules using mass cytometry. We 
also evaluated the effect of IFNγ on their sensitivity to NK cell-mediated lysis. Our results 
show upregulation of PD-L1, ICAM-1, MHC-class I, HLA-DR, CD95/FasR, and CD270/
HVEM after IFNγ treatment, this upregulation is variable across different tumor types. 
We also observed a variable impact of IFNγ in NK cell-mediated lysis. For six of the 
cancer cell lines IFNγ resulted in increased resistance to NK cells, while for three of them 
it resulted in increased sensitivity. Modeling of the data suggests that the effect of IFNγ 
on NK cell-mediated tumor lysis is mostly dependent on changes in MHC-class I and 
ICAM-1 expression. For three of the cell lines with increased resistance, we observed 
higher upregulation of MHC-class I than ICAM-1. For the cell lines with increased sensi-
tivity after IFNγ treatment, we observed upregulation of ICAM-1 exceeding MHC-class 
I upregulation. ICAM-1 upregulation resulted in increased conjugate formation between 
the NK cells and tumor cells, which can contribute to the increased sensitivity observed. 
However, the effects of MHC-class I and ICAM-1 are not readily predictable. Due to 
the high IFNγ secretion of NK cell infusion products, a better understanding of the NK 
ligands on tumor cells and how they are affected by IFNγ is essential to optimize NK cell 
immunotherapy.
Keywords: interferon gamma, natural killer cells, pediatric cancer, mass cytometry, natural killer ligands, 
immunotherapy, intercellular adhesion molecule 1, major histocompatibility complex
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inTrODUcTiOn
Current chemotherapeutic approaches for pediatric cancer are 
associated with high morbidity and late effects in survivors. By 
the age of 50, many survivors experience cardiovascular, renal, 
and hepatic complications, in addition to the risk of subsequent 
malignancies (1). Therefore, there is a need to develop new 
therapies capable of eradicating disease with reduced late effects. 
Immunotherapy has emerged as a promising new approach for 
cancer treatment. Natural killer (NK) cells, an important compo-
nent of our first-line innate immunity, have activity against tumor 
cells without prior sensitization and are increasingly recognized 
for their important role in preventing and eradicating cancer. 
Because NK cells have the ability to selectively target tumor cells 
without affecting healthy cells, they are an attractive approach for 
pediatric cancer therapy.
Natural killer cells are typically defined as CD56+/CD3− 
lymphocytes. Their activity is regulated by a series of inhibitory 
and activating receptors that recognize ligands on target cells. 
The balance between activating and inhibitory signals will 
determine whether an NK  cell is activated. The three main 
receptor families present on NK cells include natural cytotoxic-
ity receptors (NCRs), C-type lectin (CD94/NKG2), and killer 
cell immunoglobulin-like receptors (KIRs) (2). NCRs (NKp30, 
NKp44, NKp46) are activating receptors, as are CD244/2B4, 
CD226/DNAM-1, and CD314/NKG2D. KIRs and C-type lectin 
receptors may be activating or inhibitory. Among the most 
important NK cell, inhibitory receptors are the KIRs and NKG2A 
because they recognize major histocompatibility complex 
(MHC) on target cells as evidence of self, leading to inhibition 
of NK cell activity (3). Many tumor cells downregulate MHC to 
escape T cell immunity, and upregulate activating ligands, mak-
ing them susceptible targets for NK cell attack (4–7). However, 
in tumor cells where both inhibitory and activating ligands are 
present, the balance of these signals determines whether the 
NK cell is activated.
We developed an expansion protocol that allows production of 
large quantities of NK cells for adoptive immunotherapy (8). We 
have observed that, as compared to primary NK cells or IL-15-
expanded NK cells, IL-21-expanded NK cells secrete 20-fold or 
100-fold more interferon gamma (IFNγ, median 2,493 vs. 24 or 
111 pg/mL, respectively), in response to target recognition (8). 
IFNγ has been reported to upregulate the inhibitory MHC-class 
I in target cells, making them more resistant to NK cell-mediated 
lysis (9, 10). However, IFNγ has also been reported to promote 
NK:target cell interaction through upregulation of intercellular 
adhesion molecule 1 (ICAM-1), promoting increased target cell 
death (11, 12). These findings suggest that IFNγ can have oppos-
ing effects on tumor cell sensitivity to NK cell-mediated lysis. To 
optimize the use of expanded NK cells as an immunotherapy it is 
imperative that we better understand how IFNγ affects NK cell-
mediated lysis of the tumor cells.
Opposing effects reported for IFNγ may be due to a focus on 
specific tumor types, therefore this study aimed to evaluate the 
effect of IFNγ on a broad selection of 22 tumor cell lines from the 
pediatric preclinical testing program (PPTP) in vitro panel. This 
panel was designed to evaluate new therapies against childhood 
leukemias and solid tumors and has already been used for in vitro 
testing of over 50 pediatric cancer therapies (13). Using these 
cancer cells corresponding to six different types of pediatric 
malignancies, we evaluated the effects of IFNγ treatment in tumor 
cell sensitivity to NK cell-mediated lysis. Also we evaluated the 
effects of IFNγ treatment on tumor expression of NK cell ligands, 
including activating and inhibitory ligands, death receptors, and 
adhesion molecules.
MaTerials anD MeThODs
isolation and expansion of human nK 
cells
Buffy coats from four anonymized donors were obtained 
from Gulf Coast Regional Blood Center (Houston, TX, USA). 
Exemption and waiver of consent for the research use of buffy 
coat fractions obtained from anonymized donors at Gulf Coast 
Regional Blood Center (Houston, TX, USA) was granted by 
the Institutional Review Board of the University of Texas 
MD Anderson Cancer Center under protocol PA13-0978. 
NK cells were isolated using the RossetteSep Human NK cell 
enrichment cocktail (Stem Cell Technologies) and expanded 
as described previously using K562 Clone9.mbIL21 as feeder 
cells for 21 days (8). Expanded NK cells were cryopreserved, 
and subsequently thawed and recovered for 1–2 days prior to 
their use. During recovery NK cells were cultured in NK cell 
media consisting of RPMI 1640 (Corning) supplemented with 
50  IU/mL recombinant human IL-2 (Proleukin, Novartis 
Vaccines and Diagnostics, Inc.), 20% Fetal Bovine Serum 
(Thermofisher), l-glutamine (Gibco), and penicillin/strepto-
mycin (Corning).
Tumor cells
TC-71, NALM-6, and Ramos-RA1 were obtained as kind gifts 
from colleagues (Drs. Eugenie S. Kleinerman, L. J. N. Cooper, 
and J. Chandra, respectively). Karpas-299 was obtained from 
the German Collection of Microorganisms and Cell Cultures 
(DSMZ). RS4;11, MOLT-4, and CCRF-CEM were obtained from 
the America Type Culture Collection (ATCC). The remaining cell 
lines were obtained from the Children’s Oncology Group (COG) 
Cell Line and Xenograft Repository. Brain tumor cell lines BT-12, 
SJ-GBM2, CHLA-266, Ewing sarcoma (EWS) cell lines CHLA-9, 
CHLA-10, CHLA-258, TC-71, neuroblastoma (NB) cell lines 
NB1643, NB-EBc1, CHLA-90, CHLA-136, rhabdomyosar-
coma (RMS) cell line RD, and leukemia cell line COG-LL-317 
were cultured in IMDM (Lonza) supplemented with 20% FBS 
(Thermofisher), 4  mM l-glutamine (Gibco), 1× ITS (Lonza), 
and penicillin/streptomycin (Corning). Lymphoma cell lines 
Karpas-299, Ramos-RA1, leukemia cell lines NALM-6, RS4;11, 
MOLT-4, CCRF-CEM, Kasumi-1, and RMS cell lines Rh41, 
Rh30, were cultured in RPMI 1640 (Corning) supplemented with 
10% Fetal Bovine Serum (Thermofisher), l-glutamine (Gibco), 
and penicillin/streptomycin (Corning). Cultures were periodi-
cally tested to confirm absence of mycoplasma using MycoAlert 
Mycoplasma Detection Kit (Lonza). Identity was confirmed by 
STR DNA fingerprinting either using the AmpFlSTR Identifiler 
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kit (Applied Biosystems) or the Power Plex 16HS Kit (Promega) 
according to manufacturer instructions. The STR profiles were 
compared to known fingerprints as published by ATCC or the 
COG cell STR Genotype Database (http://strdb.cogcell.org). 
STR profiles were last performed on March 2016 (SJ-GBM2, 
NB1643, MOLT-4), October 2015 (RD, Rh41, Rh30, BT-12, 
CHLA-10, NB-EBc1, NALM-6, and Ramos-RA1), or September 
2012 (CHLA-266, CHLA-9, CHLA-258, TC-71, CHLA-90, 
CHLA-136, RS4;11, COG-LL-317, CCRF-CEM, Kasumi-1, and 
Karpas-299). Banks of STR validated, mycoplasma-free cell lines 
were cryopreserved. Cell lines were kept in culture no longer than 
eight passages or 4 weeks prior to use.
iFnγ Treatment of Tumor cells
Cell lines that grow in suspension were seeded at 0.5 ×  106 
cells/mL and treated with 50  ng/mL of IFNγ (Peprotech) for 
48 h. Adherent cells were cultured to a 60–70% confluence and 
treated with 50 ng/mL of IFNγ (Peprotech) for 48 h. Untreated 
tumor cells were seeded in parallel. After treatment cells were 
washed in IFNγ free media, and adherent cells were detached 
with non-enzymatic cell dissociation buffer (Gibco) to avoid 
degradation of cell surface proteins. Treated and untreated cells 
were evaluated for surface expression of NK cell ligands by mass 
cytometry and sensitivity to NK cell-mediated lysis by calcein 
release assay.
cytotoxicity
The fluorescence based calcein release assay was used to assess 
cytotoxicity, as previously described (8, 14). Adherent cells 
were detached with non-enzymatic cell dissociation buffer 
(Gibco) and cells were filtered by using a 70 μm cell strainer 
(Corning) to obtain a single-cell suspension. Target cells were 
labeled with 5 μg/mL of calcein-AM (Sigma-Aldrich) for 1  h 
at 37°C. NK cells were cocultured with target cells at different 
effector to target (E:T) ratios (10:1, 5:1, 2.5:1, 1.25:1, 0.6:1, and 
0.3:1) for 4  h at 37°C. Supernatant fluorescence was deter-
mined at 485  nmExc/530  nmEmm using the SpectraMax Plus384 
spectrophotometer.
Mass cytometry
Antibodies for mass cytometry were labeled with heavy met-
als using Maxpar-X8 labeling reagent kits (DVS Sciences) 
according to manufacturer’s instructions and titrated for 
determination of optimal concentration. The antibodies and 
their respective heavy metal labeling can be found in Table 
S1 in Supplementary Material. Since NK  cell receptors may 
have multiple ligands (e.g., NKG2D binds to MICA, MICB, 
and ULBP1-5), or unknown ligands, chimeric receptor:IgG-
Fc fusion proteins were tagged with heavy metals and used 
for identification of ligands on tumor cells. Then, 1.5 ×  106 
cells were stained for viability with 2.5  µM cell ID cisplatin 
(Fluidigm, 201064) in serum free RPMI for 1 min and washed 
twice with complete media. Subsequently, surface staining 
was performed as previously described (15). Staining media 
were prepared by adding 5% FBS and 0.1% sodium-azide to 
PBS. During the intracellular staining step of tumor cells, two 
different isotopes of cisplatin Pt-194 (Fluidigm, 201194) and 
Pt-198 (Fluidigm, 201198) were used to barcode untreated 
and IFNγ-treated samples, respectively, allowing samples to 
be combined in a single tube, minimizing acquisition time, 
and variability between runs. Data were acquired on a CyTOF 
instrument (DVS Sciences). Files containing only live single 
cells were exported using FlowJo V10 Software and uploaded 
into Cytobank for further analysis (Figure S1 in Supplementary 
Material) (16).
conjugation assay
The determination of effector conjugation to target cells was per-
formed as described by Burshtyn et al., with some minor modi-
fications (17). Briefly, NK cells and tumor cells were stained with 
green dye PKH67-GL (Sigma, MINI67) and red dye PKH26-GL 
(Sigma, MINI26), respectively, in 5 µM dye at 5 × 106 cells/mL for 
5 min at room temperature. Dye staining was stopped by adding 
two volumes of FBS and two volumes of complete media. Cells 
were washed twice with complete media and let rest for at least 
1 h at 37°C. Then, 105 NK cells were combined with 2 × 105 tumor 
cells in 200 µL, centrifuged at 20 g for 1 min (to initiate contact), 
and incubated at 37°C for 30  min. Cells were resuspended by 
gentle vortexing, fixed with 200  µL of 4% formaldehyde, and 
analyzed by flow cytometry. For antibody blocking experiments, 
NK cells were pre-incubated with 5 µL of Fc blocker (Biolegend, 
422302) for 10 min to avoid antibody-dependent cell cytotoxicity. 
ICAM-1 was blocked on tumor cells by adding 10 µg/mL of anti-
CD54/ICAM-1 clone HCD54 (Biolegend, 322703) for 20 min at 
room temperature.
statistical analysis
Statistics were performed in GraphPad Prism Software. For 
determination of Δ in % Lysis after IFNγ treatment (Figure 1), 
we used data from six different E:T ratios. For each cell line, we 
calculated the average difference in lysis after IFNγ treatment 
(%lysis IFNγ treated −  %lysis untreated) using four NK  cell 
donors. Significance was determined by using the t-test with 
a hypothetical value of 0 for comparison. Heatmaps were 
generated using Cytobank (16). Conjugation data significance 
was determined by using the t-test, statistical significance was 
determined by a p < 0.05.
resUlTs
iFnγ has a Variable impact on Tumor cell 
sensitivity to nK cell-Mediated lysis
We determined whether tumor IFNγ treatment affected NK cell-
mediated lysis for 22 pediatric cancer cell lines from the PPTP 
in vitro panel. Tumor cell lines evaluated were derived from brain 
tumors, EWS, NB, leukemia, lymphoma, and RMS. The Rh18 cell 
line was excluded because of repeated problems maintaining the 
cell line in culture. We observed that 6 of the 22 cell lines evalu-
ated show a significant decrease in NK  cell-mediated lysis after 
IFNγ treatment (Figure 1). The group of cell lines with decreased 
lysis after IFNγ treatment includes leukemia cell lines Molt-4 
(p = 0.0030) and Kasumi-1 (p = 0.0231), EWS cell lines CHLA-9 
FigUre 1 | Waterfall plot of change in lysis by natural killer (nK) cells after treatment of pediatric cancer cell lines with iFnγ. NK cell cytotoxic activity 
toward IFNγ-treated and -untreated cancer cells was evaluated using calcein release assays. Changes in lysis (Δ% Lysis) of treated compared to untreated cancer 
cells were quantified for each NK cell donor. Each shape represents a different NK cell donor (the same four donors were used for all cell lines). Color coding 
corresponds to cell line cancer type. p-Values are for probability that Δ% ≠ 0 (t-test). Squares with dashed lines indicate cancer cell lines with significant (p ≤ 0.05) 
changes in NK cell-mediated lysis after IFNγ treatment.
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(p =  0.0037) and CHLA-10 (p =  0.0292), lymphoma cell line 
Ramos-RA1 (p = 0.0007), and NB cell line CHLA-136 (p = 0.0065). 
The NB cell line NB-EBc1 appears to have a decreased lysis after 
treatment, however, it was not statistically significant. When 
decreased lysis after treatment was observed, it was consistent for 
all four donors tested and across E:T ratios (Figure 2A).
By contrast, two of the cell lines showed an increase in 
NK  cell-mediated lysis after IFNγ treatment. These cell lines 
include the glioblastoma cell line SJ-GBM2 (p = 0.0155) and 
the NB cell line NB1643 (p = 0.0371) (Figure 1). In addition, 
although the brain tumor cell line BT-12 shows a non-significant 
increase in sensitivity, we observed that for three of the four 
NK  cell donors there was an increased sensitivity after IFNγ 
treatment, this increase is significant if these three donors are 
evaluated (p = 0.0061). Increased lysis after IFNγ treatment was 
a consistent finding with most donors mostly at high NK cell 
doses (Figure 2B). The remaining cell lines evaluated showed 
no differences in NK cell-mediated lysis after IFNγ treatment, 
and this group includes cell lines corresponding to all the 
tumor types evaluated (Figure 1). After stratifying our data by 
tumor type, we can observe that the only tumor type for which 
IFNγ had no effect on lysis was RMS. In EWS, leukemia, and 
lymphoma IFNγ had no effect or resulted in decreased lysis, 
whereas IFNγ had no effect or resulted in increased lysis for 
brain tumors. Interestingly, for NB cell lines, the effect of IFNγ 
on NK cell-mediated lysis was variable. Lysis of some NB cell 
lines was unaffected by IFNγ treatment, some became more 
resistant, and some more sensitive.
FigUre 2 | iFnγ has a variable impact on natural killer (nK) cell-mediated cancer lysis. NK cell cytotoxic activity toward IFNγ-treated (gray) and -untreated 
(black) cancer cells was evaluated at six different effector to target (E:T) ratios using calcein release assays. (a) Cell lines showing decreased lysis [leukemia (Molt-4, 
Kasumi-1), Ewing sarcoma (CHLA-9, CHLA-10), lymphoma (Ramos-RA1), and neuroblastoma (NB) (CHLA-136)] and (B) cell lines showing increased lysis [brain 
tumors (BT-12, SJ-GBM2) and NB (NB1643)] after IFNγ treatment. The four NK cell donors are represented for all cell lines, except for BT-12 with three donors 
represented.
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iFnγ alters surface expression of nK cell 
ligands in Pediatric cancer cell lines
The 22 pediatric cancer cell lines obtained from the PPTP 
in vitro panel were evaluated by mass cytometry for the expres-
sion of 16 NK cell ligands. Baseline expression of NK cell ligands 
in terms of median expression and percentage positive cells is 
provided in Figure  3. The inhibitory ligands MHC-class I and 
HLA-E are homogeneously expressed (>70%) for all PPTP cell 
lines with the exception of the RMS cell line Rh41 where MHC-
class I was expressed in only 35% of the cells (Figure  3, right 
panel). Interestingly, we observe that solid tumor cell lines (RMS, 
brain tumor, EWS, and NB) have higher median expression levels 
of TRAIL receptor CD262/DR5, and ligands for the activating 
receptors NKG2D, DNAM-1, and NCRs, when compared to 
leukemia cell lines (Figure 3, left panel).
Baseline expression levels of NK cell ligands were compared 
to the levels after IFNγ treatment and changes were quantified. 
The percentage change in mean mass intensity (MMI) after 
IFNγ treatment was determined for each of the 22 cell lines 
(Figure  4A). CD274/PD-L1, CD54/ICAM-1, HLA-DR, MHC-
class I, CD95/FasR, and CD270/HVEM were the most affected 
by IFNγ (Figure 4A), with at least three cell lines showing fivefold 
increase or more in MMI. Data were also evaluated in terms of 
median expression. IFNγ induced changes in median expres-
sion were quantified, and a heatmap corresponding to the fold 
increase in median expression (obtained from the arcsinh ratio 
FigUre 3 | expression of natural killer (nK) cell ligands in pediatric cancer cell lines. Pediatric cancer cell lines were evaluated by mass cytometry for the 
baseline expression level of multiple NK cell ligands. The evaluated markers and their function can be found at the table above. Left panel: median expression level 
normalized by row minimum (obtained by evaluating the arcsinh ratio of the median expression compared to the row minimum). Right panel: percent positive cells 
for each given marker.
6
Aquino-López et al. Variable NK-Ligand Responses to IFNγ
Frontiers in Immunology | www.frontiersin.org April 2017 | Volume 8 | Article 391
of median) was generated (Figure 4B). The changes in median 
expression were similar to changes in mean expression. CD274/
PD-L1, CD54/ICAM-1, HLA-DR, MHC-class I, CD95/Fas, and 
CD270/HVEM were the markers mostly upregulated by IFNγ 
(Figure  4B). When stratified by tumor type (Figure  5; Figure 
S2 in Supplementary Material), we observe that PD-L1 was 
most upregulated by IFNγ in solid tumor cell lines (RMS, brain, 
EWS, and NB), but was relatively unaffected on leukemia and 
lymphoma cell lines. ICAM-1 upregulation was higher for brain 
tumors, EWS, NB and leukemia, and lower for RMS and lympho-
mas. HLA-DR was upregulated by IFNγ on some brain tumor, 
EWS, and NB cell lines. MHC-class I upregulation was variable 
even within the same tumor type. However, IFNγ-induced MHC-
class I upregulation was consistently observed in all NB cell lines. 
Finally, CD270/HVEM upregulation was induced by IFNγ in 
some brain tumor, EWS, and NB cell lines. Our data show that 
lymphoma cell lines were the least affected by IFNγ in terms of 
NK cell ligand expression (Figure 5; Figure S2 in Supplementary 
Material).
iFnγ-induced Upregulation of Mhc-class i 
and icaM-1 correlates with changes nK 
cell-Mediated lysis
Next, we wanted to determine whether there was a correlation 
between changes in ligand expression after IFNγ treatment and 
changes in NK cell-mediated tumor lysis. We first assessed our 
expanded NK cells for expression of the receptors corresponding 
to the most upregulated ligands—PD-L1, ICAM-1, and MHC-
class I. Expression of PD-1, the receptor for PD-L1, was observed 
on only 7% of the expanded NK cells (Figure 6). This low percent-
age of PD-1+ NK  cells in our expanded product suggests that 
PD-L1 upregulation is unlikely to play a role in the IFNγ-induced 
changes in lysis we observed.
By contrast, LFA-1, the integrin that binds ICAM-1, was 
expressed in 99.6% of our expanded NK cells (Figure 6), and inhibi-
tory KIR receptors were also highly expressed in our expanded 
NK cells. KIR2DL2/3 expression was 83.9%, KIR2DL1/2DS5 was 
97.18%, and KIR3DL1 was 89.15% (Figure 6). Also we observed 
expression of the inhibitory receptor NKG2A in 97% of expanded 
NK  cells. Knowing that the majority of our expanded NK  cells 
express LFA-1, KIR, and NKG2A receptors, we focused on 
changes in ICAM-1 and MHC-class I expression (Figure 7). The 
ratio of change in MHC-class I over change in ICAM-1 after IFNγ 
treatment was evaluated and plotted for cell lines with altered 
sensitivity (Figure  7C). We observed that all the cell lines that 
became more resistant after IFNγ treatment had an increase in 
MHC-class I expression (Figures 2A and 7A). However, MHC-
class I upregulation was also observed in some of the cell lines 
with increased sensitivity after IFNγ treatment (Figures 2B and 
7B). Interestingly, MHC-class I/ICAM-1 change ratio was <1 and, 
indicating that upregulation of ICAM-1 exceeded MHC-class I 
upregulation, for all the cell lines with increased sensitivity after 
IFNγ treatment (Figures  7B,C). The opposite pattern, with an 
MHC-class I/ICAM-1 change ratio >1 and MHC-class I upregu-
lation exceeding ICAM-1 upregulation, was observed in three 
of the six cell lines where IFNγ induced resistance (Kasumi-1, 
MOLT-4, and CHLA-136) (Figures  7A,C). However, ICAM-1 
upregulation exceeded MHC-class I upregulation (ratio <1) in 
FigUre 4 | impact of iFnγ treatment on the surface expression of natural killer (nK) cell ligands for pediatric cancer cell lines. (a) Change in 
expression level [mean mass intensity (MMI)] was determined by quantifying the mean of each parameter at baseline and after IFNγ treatment for each cell line. 
Percent change in MMI after IFNγ treatment was calculated for each cell line and box plots were generated for each parameter using data obtained from all 22 cell 
lines. (B) Fold change in median expression for each parameter in all cell lines. Heat corresponds to the fold change in median expression after IFNγ treatment 
(obtained as the arcsinh ratio of median expression for the given markers compared to untreated cell line control). Cancer type color coding is the same as in 
Figure 1. Squares with dashed lines indicate cancer cell lines with significant changes in NK cell-mediated lysis after IFNγ treatment.
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the EWS cell lines CHLA-9 and CHLA-10 and the lymphoma cell 
line Ramos-RA1, for which IFNγ treatment resulted in decreased 
NK cell-mediated lysis.
iFnγ-induced icaM-1 Upregulation 
increases conjugate Formation for cell 
lines with increased sensitivity
Since IFNγ is known to enhance MHC-class I expression, 
resulting in resistance of target cells to NK  cell-mediated lysis 
(9, 10), we investigated possible mechanisms for the enhanced 
sensitivity observed after treatment for the cell lines SJ-GBM2, 
NB1643, and BT-12. These showed increased sensitivity to 
NK  cell-mediated lysis after IFNγ treatment despite presence 
of high levels of MHC-class I. Since upregulation of the adhe-
sion molecule ICAM-1 exceeded MHC-class I upregulation for 
these tumors, we determined whether IFNγ-mediated ICAM-1 
upregulation was capable of overcoming MHC-class I inhibition 
through increased conjugate formation between the NK cells and 
the target cells (Figure 8A). For comparison, we also evaluated 
IFNγ-mediated changes in conjugate formation between NK cells 
and Ramos-RA1, a cell line having high ICAM-1 expression but 
for which IFNγ resulted in more resistance. We observed that 
treatment of BT-12, SJ-GBM2, and NB1643 with IFNγ resulted in 
increased conjugate formation (Figure 8B) and this was statisti-
cally significant for BT-12 (p = 0.026) and SJ-GBM2 (p = 0.011). 
By contrast, IFNγ treatment did not increase conjugate forma-
tion for Ramos-RA1. Next, to confirm whether the increased 
conjugate formation was specifically mediated by ICAM-1 
upregulation, we used monoclonal antibodies to block ICAM-1 
on IFNγ-treated cells (BT-12, SJ-GBM2, and NB1643). Blocking 
of ICAM-1 resulted in a significant decrease in conjugate forma-
tion for BT-12 (p = 0.042), SJ-GBM2 (p = 0.008), and NB1643 
(p = 0.041) (compared to isotype control, Figure 8C).
DiscUssiOn
Natural killer cells are an attractive approach for cancer immuno-
therapy. Our laboratory has developed an ex vivo NK cell expan-
sion platform that allows us to generate large quantities of NK cells 
for patient infusion. We have shown that our expanded NK cells, 
currently used in several clinical trials for myeloid malignancies 
and posterior fossa tumors (NCT01787474, NCT01904136, 
NCT01823198, NCT02271711), secrete large amounts of IFNγ 
compared to primary NK  cells (8). Similarly, memory-like 
NK  cells used for adoptive transfer to AML patients exhibited 
enhanced IFNγ production when compared to control NK cells 
FigUre 6 | Phenotyping of expanded natural killer (nK) cells. 
Expression of PD-1, LFA-1, killer cell immunoglobulin-like receptors (KIRs), 
and NKG2A on the expanded NK cells was obtained by mass cytometry 
(n = 4 donors).
FigUre 5 | Major ligands affected by iFnγ classified by tumor type. IFNγ induced changes in NK cell ligand expression were evaluated by cancer type. Y-axis 
corresponds to the fold increase in marker median expression after IFNγ treatment, this was obtained by evaluating the arcsinh ratio of median expression for the 
given marker compared to untreated cell line.
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(18). Due to the high levels of IFNγ secreted by NK cell infusion 
products, we sought to determine the effects of IFNγ on NK cell 
interactions with the tumor cells.
Through this study we evaluated a broad selection of pediatric 
tumor cells, representing at least six different types of malignan-
cies, for the effect of IFNγ on their sensitivity to NK cell-mediated 
lysis using expanded NK cells from four independent donors. This 
enabled a broad study across tumor types demonstrating oppos-
ing effects of IFNγ, a finding that may not have been evident in 
other studies that focus on a single tumor type or modulation of 
a single surface ligand. Of the 22 cell lines evaluated, six showed 
a significant decrease in NK cell-mediated lysis after IFNγ treat-
ment, including leukemia, EWS, lymphoma, and NB  cells. By 
contrast, treatment with IFNγ resulted in enhanced sensitivity to 
NK cells for three cell lines, BT-12, SJ-GBM2, and NB1643 (two 
brain tumors and a NB, respectively). For the remaining cell lines, 
IFNγ treatment did not significantly affect NK cell-mediated lysis, 
though some showed trends that may be significant with more 
donor replicates. The effect of IFNγ treatment was variable within 
the same tumor type, with the exception of RMS cell lines for which 
IFNγ treatment had no effect. These results suggest that the effect 
of IFNγ on NK cell-mediated lysis of tumor cells is variable and 
cell line dependent. Our findings warrant more focused investiga-
tion and validation for specific tumor types using primary tumor 
samples or patient-derived xenografts where feasible.
To better understand this variability, we used mass cytometry to 
evaluate the effect of IFNγ on expression of NK cell ligands by cancer 
cells. First, we observed broad heterogeneity in baseline expression 
levels of ligands between and within tumor types (Figure 3B). Solid 
tumor cell lines had higher median expression of TRAIL receptor 
FigUre 7 | effect of iFnγ treatment on intercellular adhesion molecule 1 (icaM-1) and major histocompatibility complex (Mhc)-class i expression 
for cancer cell lines with altered sensitivity. The effect of IFNγ on ICAM-1 and MHC-class I expression for cell lines in which IFNγ treatment conferred  
(a) resistance or (B) sensitivity to NK cell-mediated lysis. Histograms compare ICAM-1 (left) and MHC-class I (right) expression for untreated cancer cells (top) and 
IFNγ-treated cells (bottom). Bar graphs represent ICAM-1 and MHC-class I fold change in median expression after IFNγ treatment. (c) Ratio of MHC-class I/ICAM-1 
change after IFNγ treatment for cell lines with altered sensitivity. Fold change in median expression after IFNγ treatment for each parameter was quantified and the 
ratio was calculated. Ratio <1 indicates higher ICAM-1 upregulation and ratio >1 indicates higher MHC-class I upregulation after IFNγ treatment.
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CD262/DR5 and ligands for the activating receptors NKG2D, 
DNAM-1, and NCRs, compared to leukemia cell lines (Figure 3A). 
This suggests NK cells may be a promising therapy for solid tumors. 
We also observed that none of these ligands were downregulated 
by IFNγ; however, CD274/PD-L1, CD54/ICAM-1, HLA-DR, 
MHC-class I, CD95/FasR, and CD270/HVEM were upregulated in 
a variety of tumor types. Other than CD270/HVEM, these findings 
are consistent with previously published studies (11, 12, 19–24). 
HVEM is involved in T cell regulation (25), but no studies have yet 
reported regulation of this ligand by IFNγ and its role in NK cell 
biology has not been well described.
Although IFNγ-mediated upregulation of MHC-class I, PD-L1, 
and ICAM-1 has been previously described, this study uncovers 
the variability of IFNγ responses across different pediatric tumor 
types. In terms of PD-L1, our results show upregulation by IFNγ 
for most pediatric solid cancers (RMS, brain tumors, EWS, and 
NB), but no effect on pediatric leukemia and lymphoma cells. On 
the other hand, the adhesion molecule ICAM-1 was upregulated 
by IFNγ on brain tumors, EWS, NB, and leukemia, but not on 
RMS and lymphoma cells. Although IFNγ-induced ICAM-1 
upregulation has been previously described in NB and leukemia 
cells (11, 12), to our knowledge no studies have shown its upregu-
lation on EWS.
According to our data, the ligands most upregulated by IFNγ 
were PD-L1, ICAM-1, and MHC-class I; therefore, we deter-
mined whether changes in their expression correlated to changes 
in tumor lysis after IFNγ treatment. PD-1/PD-L1 is associated 
with immune cell suppression; however, we observed that <7% 
of expanded NK  cells express PD-1. In addition, changes in 
expression of PD-L1 did not correlate with changes in cytotox-
icity, suggesting that PD-L1 did not play a role in our model. 
By contrast, changes in ICAM-1 and MHC-class I cooperate 
in affecting NK cell responsiveness. For the cell lines in which 
IFNγ increased sensitivity to NK  cells, we observed ICAM-1 
upregulation exceeding MHC-class I upregulation (MHC-class 
I/ICAM-1 < 1). This suggests that the LFA-1/ICAM-1 interaction 
augments NK cell-mediated lysis even in the presence of high lev-
els of inhibitory MHC-class I molecules. MHC-class I molecules 
mediate NK cell inhibition through binding with KIRs (HLA-A, 
HLA-B, HLA-C) and NKG2A (HLA-E). The anti-MHC-class 
I antibody clone used in this study, W6/32, recognizes both 
classical (HLA-A, HLA-B, HLA-C) and non-classical (HLA-E) 
HLA (26). We observed that for three of the six cell lines with 
increased resistance after IFNγ treatment, MHC-class I upregula-
tion exceeded ICAM-1 upregulation (MHC-class I/ICAM-1 >1). 
This suggests that the NK cell balance was shifted toward inhibi-
tion due to the increased expression of MHC-class I, which binds 
NK  cell inhibitory receptors. However, in the other three cell 
lines with increased resistance after IFNγ treatment we observed 
that ICAM-1 upregulation exceeded MHC-class I upregulation 
(MHC-class I/ICAM-1 <1) for which this model would have 
predicted increased sensitivity after IFNγ treatment. Our results 
suggest that the differential effects on MHC-class I and ICAM-1 
expression can explain some but not all of the effects of IFNγ on 
sensitivity to NK cell lysis.
We investigated possible mechanisms for the enhanced sensi-
tivity observed after IFNγ treatment for the cell lines SJ-GBM2, 
NB1643, and also BT-12. After IFNγ treatment these cell lines 
showed increased sensitivity to NK cell-mediated lysis, even in 
the presence of high levels of MHC-class I (Figures 2B and 7B). 
Since IFNγ treatment caused ICAM-1 upregulation exceeding 
MHC-class I upregulation in these cells lines (MHC-class I/
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ICAM-1 <1), we evaluated conjugate formation after IFNγ 
treatment. Our results show an increase in the formation of 
conjugates between the NK cells and the target cells SJ-GBM2, 
BT-12, and NB1643 after IFNγ treatment, and conjugate forma-
tion was decreased for IFNγ-treated cells after blocking ICAM-1 
on the target cells. Ramos-RA1 did not show increased conjugate 
formation or killing in response to IFNγ, possibly because it has 
such high baseline ICAM-1 expression and conjugate formation. 
FigUre 8 | conjugation assay for cell lines with increased sensitivity after iFnγ treatment. (a) y-Axis represents fluorescence of labeled target cells and 
x-axis represents fluorescence of labeled natural killer (NK) cells, and Q2 indicates dual fluorescence of NK cells conjugated with target cells. (B) Quantification of 
%NK cells in conjugate with BT-12, SJ-GBM2, NB1643, and Ramos-RA1. (c) Quantification of %NK cells in conjugate after ICAM-1 block for IFNγ-treated BT-12, 
SJ-GBM2, and NB1643 (n = 3 donors, Student’s t-test).
This suggests that the mechanism of increased sensitivity from 
IFNγ treatment is, at least in part, mediated by increased ICAM-1 
upregulation leading to enhanced effector-target conjugation.
Our study uncovers the complexity behind cancer cell responses 
to IFNγ. Published literature has shown increased resistance to 
NK cell-mediated lysis due to MHC-class I upregulation in some 
cancers (9, 10), but increased sensitivity to NK cell-mediated lysis 
due to ICAM-1 upregulation in others (11, 12). These studies 
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